Medical Oncology

Doç. Dr. Hatice Bölek

Doctor and researcher Ankara Bilkent Şehir Hastanesi Ankara
Carcinoma, Renal CellKidney NeoplasmsProstatic NeoplasmsStomach NeoplasmsNeoplasmsLung NeoplasmsInfluenza, Human
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Carcinoma, Renal Cell 14 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Kidney Neoplasms 14 publications
  • Prostatic Neoplasms 3 publications
  • Stomach Neoplasms 2 publications
  • Neoplasms 2 publications
  • Lung Neoplasms 2 publications
  • Influenza, Human 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionAnkara Bilkent Şehir Hastanesisaglik.gov.trFrom source
  • Area of workCarcinoma, Renal CellExtracted from 14 publications · Model version —From source
  • Publications74 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0001-8659-7327ORCIDFrom source
  • Last synchronised5 November 2026 07:23https://ankarasehir.saglik.gov.tr/TR-331078/tibbi-onkoloji-klinigi-doktorlarimiz.html#hatice-boleksaglik.gov.tr

Scientific work

Publications on Carcinoma, Renal Cell

74 publications

  1. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

    Medicina, 2026

    DOI 10.3390/medicina62050984 PMID 42195237 Open-access full textSource: OpenAlex

  2. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Open-access full textSource: OpenAlex

  3. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Open-access full textSource: OpenAlex

  4. Real-world treatment patterns and survival outcomes in HER2-positive metastatic gastric cancer

    Akademik Gastroenteroloji Dergisi, 2026

    DOI 10.17941/agd.1987603 Open-access full textSource: ORCID

  5. Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco-25-02722 PMID 41849717 Source: ORCID

  6. Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration-Sensitive Prostate Cancer

    The Prostate, 2026

    DOI 10.1002/pros.70062 PMID 40993982 2 citations (Europe PMC) Source: ORCID

  7. Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations

    The Oncologist, 2026

    DOI 10.1093/oncolo/oyag203 PMID 42159577 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  8. Prognostic Impact of Intraductal Carcinoma in Patients with Metastatic Prostate Cancer Treated with Abiraterone Acetate or Enzalutamide

    Bulletin of Urooncology, 2026

    DOI 10.4274/uob.galenos.2026.2025.12.1 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  9. Aspirin use and outcomes with immune checkpoint inhibitors in metastatic cancer.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e14584 1 citation (OpenAlex) Source: OpenAlex

  10. Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-35435-3 PMID 41548007 1 citation (OpenAlex) Open-access full textSource: OpenAlex

View all 74 publications